Bristol-Myers Squibb Co. (BMY) financial statements: income statement, balance sheet and cash flow

Bristol-Myers Squibb Co.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Bristol-Myers Squibb Co. reported revenue of $48.2B (-0.2% year on year) and net income of $7.1B (+179.0% year on year).

Income statement

Bristol-Myers Squibb Co. income statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Total Revenues	$48.2B	$48.3B	$45.0B	$46.2B
Cost of products sold	$13.9B	$14.0B	$10.7B	$10.1B
Selling, general and administrative	$7.3B	$8.4B	$7.8B	$7.8B
Research and development	$10.0B	$11.2B	$9.3B	$9.5B
Acquired IPRD	$3.7B	$13.4B	$913.0M	$815.0M
Amortization of acquired intangible assets	$3.3B	$8.9B	$9.0B	$9.6B
Other (income)/expense, net	$674.0M	$893.0M	($1.2B)	$576.0M
Total Expenses	$38.9B	$56.7B	$36.6B	$38.4B
Earnings/(Loss) before income taxes	$9.3B	($8.4B)	$8.4B	$7.7B
Income tax provision	$2.3B	$554.0M	$400.0M	$1.4B
Net earnings/(loss)	$7.1B	($8.9B)	$8.0B	$6.3B
Noncontrolling Interest	$2.0M	$15.0M	$15.0M	$18.0M
Net earnings/(loss) attributable to BMS	$7.1B	($8.9B)	$8.0B	$6.3B
Basic (in dollars per share)	$3.47	-$4.41	$3.88	$2.97
Diluted (in dollars per share)	$3.46	-$4.41	$3.86	$2.95

Bristol-Myers Squibb Co. income statement, quarters

Line item	Jun 30, 2026 · Q2	Mar 31, 2026 · Q1	Sep 30, 2025 · Q3	Jun 30, 2025 · Q2
Total Revenues	$13.0B	$11.5B	$12.2B	$12.3B
Cost of products sold	$3.7B	$3.4B	$3.4B	$3.4B
Selling, general and administrative	$1.8B	$1.6B	$1.8B	$1.7B
Research and development	$3.0B	$2.6B	$2.5B	$2.6B
Acquired IPRD	$0	$94.0M	$633.0M	$1.5B
Amortization of acquired intangible assets	$437.0M	$437.0M	$831.0M	$830.0M
Other (income)/expense, net	($61.0M)	$32.0M	($108.0M)	$494.0M
Total Expenses	$8.9B	$8.3B	$9.1B	$10.5B
Earnings/(Loss) before income taxes	$4.1B	$3.2B	$3.1B	$1.8B
Income tax provision	$770.0M	$561.0M	$919.0M	$460.0M
Net earnings/(loss)	$3.3B	$2.7B	$2.2B	$1.3B
Noncontrolling interest	($1.0M)	$1.0M	($6.0M)	$2.0M
Net earnings/(loss) attributable to BMS	$3.3B	$2.7B	$2.2B	$1.3B
Basic (usd per share)	$1.62	$1.31	$1.08	$0.64
Diluted (usd per share)	$1.62	$1.31	$1.08	$0.64

Balance sheet

Bristol-Myers Squibb Co. balance sheet, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Cash and cash equivalents	$10.2B	$10.3B	$11.5B	$9.1B
Marketable debt securities	$464.0M	$513.0M	$816.0M	$130.0M
Receivables	$11.4B	$10.7B	$10.9B	$9.9B
Inventories	$2.7B	$2.6B	$2.7B	$2.3B
Other current assets	$4.6B	$5.6B	$5.9B	$5.8B
Total Current assets	$29.4B	$29.8B	$31.8B	$27.3B
Property, plant and equipment	$7.5B	$7.1B	$6.6B	$6.3B
Goodwill	$21.8B	$21.7B	$21.2B	$21.1B
Other intangible assets	$19.1B	$23.3B	$27.1B	$35.9B
Deferred income taxes	$5.4B	$4.2B	$2.8B	$1.3B
Marketable debt securities	$396.0M	$320.0M	$364.0M	—
Other non-current assets	$6.5B	$6.1B	$5.4B	$4.9B
Total Assets	$90.0B	$92.6B	$95.2B	$96.8B
Short-term debt obligations	$2.3B	$2.0B	$3.1B	$4.3B
Accounts payable	$3.6B	$3.6B	$3.3B	$3.0B
Other current liabilities	$17.6B	$18.1B	$15.9B	$14.6B
Total Current liabilities	$23.4B	$23.8B	$22.3B	$21.9B
Deferred income taxes	$222.0M	$369.0M	$338.0M	$2.2B
Long-term debt	$42.9B	$47.6B	$36.7B	$35.1B
Other non-current liabilities	$5.0B	$4.5B	$6.4B	$6.6B
Total Liabilities	$71.5B	$76.2B	$65.7B	$65.7B
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,510 in 2025 and 2,868 in 2024, liquidation value of $50 per share	$0.00	$0.00	$0.00	$0.00
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2025 and 2024	$292000000.00	$292000000.00	$292000000.00	—
Capital in excess of par value of stock	$46.4B	$46.0B	$45.7B	$45.2B
Accumulated other comprehensive loss	($1.5B)	($1.2B)	($1.5B)	($1.3B)
Retained earnings	$16.9B	$14.9B	$28.8B	$25.5B
Less cost of treasury stock — 887 million common shares in 2025 and 894 million common shares in 2024	-43.6B	-43.7B	-43.8B	-38.6B
Total BMS Shareholders’ Equity	$18.5B	$16.3B	$29.4B	$31.1B
Noncontrolling interest	$33.0M	$53.0M	$55.0M	$57.0M
Total Equity	$18.5B	$16.4B	$29.5B	$31.1B
Total Liabilities and Equity	$90.0B	$92.6B	$95.2B	$96.8B
Preferred stock, shares outstanding (in shares)	2.5K	2.9K	—	—
Preferred stock, shares issued (in shares)	2.5K	2.9K	—	—

Bristol-Myers Squibb Co. balance sheet, quarters

Line item	Jun 30, 2026	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025
Cash and cash equivalents	$8.7B	$9.6B	$15.7B	$12.6B
Marketable debt securities	$2.3B	$912.0M	$776.0M	$1.0B
Receivables	$10.6B	$9.4B	$11.4B	$11.4B
Inventories	$2.7B	$2.8B	$2.8B	$2.7B
Other current assets	$4.2B	$4.6B	$4.9B	$5.5B
Total Current assets	$28.6B	$27.2B	$35.6B	$33.2B
Property, plant and equipment	$7.8B	$7.7B	$7.3B	$7.4B
Goodwill	$21.7B	$21.7B	$21.7B	$21.8B
Other intangible assets	$17.4B	$18.2B	$20.5B	$21.4B
Deferred income taxes	$5.4B	$5.2B	$5.0B	$4.6B
Marketable debt securities	$397.0M	$366.0M	$406.0M	$346.0M
Other non-current assets	$6.4B	$6.1B	$6.3B	$5.9B
Total Assets	$87.6B	$86.5B	$96.9B	$94.7B
Short-term debt obligations	$1.0B	$2.3B	$4.5B	$4.7B
Accounts payable	$4.2B	$4.2B	$4.3B	$5.4B
Other current liabilities	$13.5B	$12.6B	$19.3B	$17.4B
Total Current liabilities	$18.7B	$19.2B	$28.1B	$27.5B
Deferred income taxes	$222.0M	$211.0M	$225.0M	$247.0M
Long-term debt	$42.1B	$42.2B	$44.5B	$44.5B
Other non-current liabilities	$4.3B	$4.9B	$5.5B	$4.9B
Total Liabilities	$65.3B	$66.4B	$78.3B	$77.2B
Preferred stock	$0	$0	$0	$0
Common stock	$292.0M	$292.0M	$292.0M	$292.0M
Capital in excess of par value of stock	$46.5B	$46.4B	$46.3B	$46.1B
Accumulated other comprehensive loss	($1.3B)	($1.4B)	($1.5B)	($1.6B)
Retained earnings	$20.3B	$18.3B	$17.1B	$16.2B
Less cost of treasury stock	($43.5B)	($43.5B)	($43.6B)	($43.6B)
Total BMS Shareholders’ equity	$22.3B	$20.1B	$18.6B	$17.4B
Noncontrolling interest	$0	$34.0M	$48.0M	$54.0M
Total Equity	$22.3B	$20.1B	$18.6B	$17.5B
Total Liabilities and Equity	$87.6B	$86.5B	$96.9B	$94.7B

Cash flow statement

Bristol-Myers Squibb Co. cash flow statement, fiscal years

Line item	Dec 31, 2025 · FY	Dec 31, 2024 · FY	Dec 31, 2023 · FY	Dec 31, 2022 · FY
Net earnings/(loss)	$7.1B	($8.9B)	$8.0B	$6.3B
Depreciation and amortization, net	$4.0B	$9.6B	$9.8B	$10.3B
Deferred income taxes	($965.0M)	($2.1B)	($3.3B)	($2.7B)
Stock-based compensation	$553.0M	$507.0M	$518.0M	$457.0M
Impairment charges	$1.1B	$3.0B	$255.0M	$179.0M
Divestiture gains and royalties	($1.2B)	($1.1B)	($884.0M)	($1.1B)
Acquired IPRD	$3.7B	$13.4B	$913.0M	$815.0M
Equity investment (gains)/losses, net	($280.0M)	($16.0M)	$160.0M	$801.0M
Contingent consideration fair value adjustments	$351.0M	—	($8.0M)	($9.0M)
Other adjustments	$232.0M	$94.0M	$308.0M	$232.0M
Receivables	($295.0M)	$264.0M	($995.0M)	($663.0M)
Inventories	($184.0M)	($486.0M)	($751.0M)	($69.0M)
Accounts payable	($2.0M)	$184.0M	$198.0M	$109.0M
Rebates and discounts	($441.0M)	$1.5B	$904.0M	$427.0M
Income taxes payable	($4.0M)	($1.3B)	($603.0M)	($1.4B)
Other	$471.0M	$624.0M	($667.0M)	($610.0M)
Net cash provided by operating activities	$14.2B	$15.2B	$13.9B	$13.1B
Sale and maturities of marketable debt securities	$2.0B	$1.1B	$733.0M	$6.4B
Purchase of marketable debt securities	($2.0B)	($769.0M)	($1.8B)	($3.6B)
Proceeds from sales of equity investments	$77.0M	$265.0M	$215.0M	—
Capital expenditures	($1.3B)	($1.2B)	($1.2B)	($1.1B)
Divestiture and other proceeds	$1.1B	$1.1B	$909.0M	$1.3B
Acquisition and other payments, net of cash acquired	($3.9B)	($21.8B)	($1.2B)	($4.3B)
Net cash provided by/(used in) investing activities	($4.1B)	($21.4B)	($2.3B)	($1.1B)
Proceeds from issuance of short-term debt obligations	$0	$3.0B	—	—
Repayments of short-term debt obligations	$0	($3.0B)	—	—
Other short-term financing obligations, net	$25.0M	$99.0M	—	—
Proceeds from issuance of long-term debt	$5.7B	$12.9B	$4.5B	$5.9B
Repayments of long-term debt	($10.9B)	($2.9B)	($3.9B)	($11.4B)
Repurchase of common stock	$0	$0	($5.2B)	($8.0B)
Dividends	($5.0B)	($4.9B)	($4.7B)	($4.6B)
Stock option proceeds and other, net	($128.0M)	($106.0M)	$27.0M	$984.0M
Net cash provided by/(used in) financing activities	($10.3B)	$5.1B	($9.4B)	($17.0B)
Effect of exchange rates on cash, cash equivalents and restricted cash	$195.0M	($137.0M)	$45.0M	($33.0M)
Increase/(decrease) in cash, cash equivalents and restricted cash	($129.0M)	($1.2B)	$2.2B	($5.0B)
Cash, cash equivalents and restricted cash at beginning of period	$10.3B	$11.5B	$9.3B	$14.3B
Cash, cash equivalents and restricted cash at end of period	$10.2B	$10.3B	—	—

Bristol-Myers Squibb Co. cash flow statement, quarters

Line item	Jun 30, 2026 · YTD	Mar 31, 2026 · Q1	Sep 30, 2025 · YTD	Jun 30, 2025 · YTD
Net earnings/(loss)	$6.0B	$2.7B	$6.0B	$3.8B
Depreciation and amortization, net	$1.2B	$594.0M	$3.0B	$2.0B
Deferred income taxes	($34.0M)	$161.0M	($573.0M)	($214.0M)
Stock-based compensation	$281.0M	$146.0M	$420.0M	$281.0M
Impairment charges	$834.0M	$412.0M	$514.0M	$318.0M
Divestiture gains and royalties	($176.0M)	($34.0M)	($880.0M)	($585.0M)
Acquired IPRD	$94.0M	$94.0M	$2.3B	$1.7B
Equity investment (gains)/losses, net	($248.0M)	($134.0M)	($90.0M)	$100.0M
Contingent consideration fair value adjustments	$0	—	$336.0M	$336.0M
Other adjustments	$22.0M	$21.0M	($76.0M)	($2.0M)
Receivables	$504.0M	$1.7B	($314.0M)	($469.0M)
Inventories	($22.0M)	$14.0M	($255.0M)	($165.0M)
Accounts payable	$380.0M	$409.0M	$88.0M	($72.0M)
Rebates and discounts	($3.1B)	($3.5B)	$2.0B	$254.0M
Income taxes payable	($335.0M)	$187.0M	$320.0M	($567.0M)
Other	($850.0M)	($1.6B)	($597.0M)	($837.0M)
Net cash provided by operating activities	$4.5B	$1.1B	$12.2B	$5.9B
Sale and maturities of marketable debt securities	$964.0M	$359.0M	$1.6B	$744.0M
Purchase of marketable debt securities	($2.9B)	($781.0M)	($1.9B)	($1.3B)
Proceeds from sales of equity investments	$429.0M	$391.0M	$61.0M	$12.0M
Capital expenditures	($652.0M)	($347.0M)	($941.0M)	($621.0M)
Divestiture and other proceeds	$521.0M	$312.0M	$792.0M	$513.0M
Acquisition and other payments, net of cash acquired	($156.0M)	($65.0M)	($2.2B)	($363.0M)
Net cash provided by/(used in) investing activities	($1.7B)	($131.0M)	($2.7B)	($972.0M)
Other short-term financing obligations, net	$191.0M	$321.0M	$431.0M	$426.0M
Repayments of long-term debt	($1.7B)	($500.0M)	($872.0M)	($643.0M)
Dividends	($2.6B)	($1.3B)	($3.8B)	($2.5B)
Stock option proceeds and other, net	($91.0M)	($98.0M)	($95.0M)	($92.0M)
Net cash provided by/(used in) financing activities	($4.2B)	($1.6B)	($4.3B)	($2.8B)
Effect of exchange rates on cash, cash equivalents and restricted cash	($58.0M)	($48.0M)	$190.0M	$194.0M
Increase/(decrease) in cash, cash equivalents and restricted cash	($1.5B)	($635.0M)	$5.4B	$2.3B
Cash, cash equivalents and restricted cash at beginning of period	$10.2B	$10.2B	$10.3B	$10.3B
Cash, cash equivalents and restricted cash at end of period	$8.7B	$9.6B	$15.7B	$12.6B

Bristol-Myers Squibb Co. score and earnings-call analysis · All covered companies

Figures as reported in SEC filings. General information, not investment advice.